Slide 1: Commercialising The Felix Device: A unique device to treat male infertility
For personal use only ASX: MEM Commercialising The Felix Device: A unique device to treat male infertility Investor Presentation June 2020 Alison Coutts Executive Chairman, Memphasys Limited
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is not and does not form part of any To the fullest extent permitted by law, Memphasys and offer, invitation or recommendation in respect of its affiliates and their respective officers, directors, securities. Any decision to buy or sell Memphasys e
Slide 3: Memphasys Value Proposition
Memphasys Value Proposition For personal use only Novel sperm selection technology for improved IVF treatments Addressing the significant global IVF market – anticipated to grow from ~ 2.3m live IVF cycles to ~4m live IVF cycles by 20261 Early markets for commercial sales represent ~24% of global IV
Slide 4: Corporate Snapshot
Corporate Snapshot ASX Code MEM Board of Directors For personal use only Alison Coutts – Executive Chairman Share price (as at 23/6/2020) $0.052 Extensive experience across a number of industry sectors and disciplines including international Shares on issue 753.97 million engineering project managem
Slide 5: The Problem: IVF tech insufficient to counter declining human fertility
The Problem: IVF tech insufficient to counter declining human fertility For personal use only • Human IVF fertility rates in decline • IVF expanding fast but success rate remains low • Average of 2.2 IVF cycles before success but no guarantee of success • IVF increases risk of miscarriage and geneti
Slide 6: The Problem: Current IVF Methods
The Problem: Current IVF Methods For personal use only • No standard method for preparing sperm for IVF • Common techniques are: o Swim-up Or o Density Gradient Centrifugation (DGC) Combination • Costs between A$80 to $100 (for each technique) per cycle • Each method takes 30 minutes or more to comp
Slide 7: Robust Demand for IVF
Robust Demand for IVF For personal use only Fresh IVF Cycles Market Value Fresh IVF Cycles (Millions) (US $ Billions) 5 19 17.6 4 17 Fresh IVF Cycles (millions) 3.9 Market Value (US$ Billions) 3.54 16 3.28 3 15 2.96 14.6 2.68 2.46 13.3 2.24 13 2 2.02 1.85 12 11 11 1 10 9 8.7 0 7.9 18 19 20 21 22 23
Slide 8: A Solution: Memphasys Felix Device
A Solution: Memphasys Felix Device For personal use only • A world-first technology to separate best quality sperm with potential to increase: • The likelihood of pregnancy • Live birth • Having a healthy baby • Quick, efficient and operator independent (6 minutes, fully automated) • Uses patented i
Slide 9: How Does the Felix Device Work?
How Does the Felix Device Work? For personal use only • Gentle electric force applied to cartridge sample • Best quality (negatively charged) sperm* attracted to positive electrode • Sperm separates through polymer membranes to: • Separate by their cell size • Eliminate white cells & other debris *
Slide 10: Semen Sample Before & After Felix Treatment
Semen Sample Before & After Felix Treatment For personal use only Prototype cartridge performance on healthy human ejaculate Sample before treatment After treatment – 6 minutes Macrocephalic (large head) Dead Viable • Separation of Viable Sperm; no debris sperm sperm • Intact membranes and acrosomes
Slide 11: KOL Program Underway
KOL Program Underway For personal use only • Key Opinion Leaders (KOLs) are international leading andrology centres and laboratories in the IVF industry • Selected for • technical and academic expertise • geographic market positioning • value to commercialisation strategy • Devices already received
Slide 12: KOL Feedback To-Date
KOL Feedback To-Date For personal use only • Highly positive initial feedback from the KOLs • Testing so far has shown: Successfull separation of sperm from samples Improved average progressive motility Quick (6min), faster than swim-up/DGC (30 min each) Easy to operate • Protocol A assessme
Slide 13: Pathway to Market
Pathway to Market For personal use only • Commercial sales expected to occur in Q4 CY2020, following successful V&V 1, 2 • Initial commercial pathway to focus on selected countries aligned to the Company’s objectives to get early sales in relatively low regulatory markets • Most likely initial marke
Slide 14: Memphasys' Business Model
Memphasys’ Business Model For personal use only • The device consists of a console and single use cartridges • The console supplies the electricity and operates the device • The cartridges contain the cell separation technology • When the device is sold commercially, IVF practitioners will require a
Slide 15: Expected Development Plan - Flow Chart
EXPECTED DEVELOPMENT PLAN - FLOW CHART Q1 2020 Q2 2020 Q3 2020 Q4 2020 H1 2021 H2 2021 For personal use only FELIX • Feedback (Monash IVF) Manufactured • Verification Tests Prototypes • KOL Assessment Usability Certified Cleanroom with Manufacturing Capability Design and preparation for Clinical Tri
Slide 16: Assisted Reproduction: Strategic Focus
Assisted Reproduction: Strategic Focus For personal use only Human ART Animal ART/AI • The major focus is to • The parallel and growing commercialise Felix and to focus is positioning to launch it into the human IVF develop a next generation market. device for artificial insemination (AI) for select
Slide 17: Equine AI: The Initial Livestock Focus
Equine AI: The Initial Livestock Focus Memphasys is working on novel designs of a new device to prepare For personal use only sperm for AI, the main way that assisted reproduction is commercially performed in livestock* New device needed to handle much larger volumes and higher sperm density than th
Slide 18: Investment Highlights
Investment Highlights For personal use only Novel sperm selection technology for improved IVF treatments Potential to counteract male infertility and disrupt IVF industry International commercial product roll out from Q4 2020 Addressing the significant global IVF market – anticipated to grow from ~
Slide 19: Thank you
For personal use only ASX: MEM Thank you Alison Coutts Executive Chairman, Memphasys Ltd 30-32 Richmond Rd, Homebush NSW 2140 Australia Phone: +612 8415 7300 www.memphasys.com.au 19